Cabaletta Bio’s Post

We are delighted to announce the appointment of Sarah Yuan, PhD as Chief Technology Officer of Cabaletta Bio! Dr. Yuan brings over two decades of cell therapy manufacturing and supply chain experience including as a member of the leadership team that developed, launched and commercialized Abecma. Please join us in welcoming Sarah to the Crew! #CabaCrew #welcome #celltherapy #autoimmune

Today, Cabaletta Bio reported our 2nd quarter earnings and provided a business update. Nine patients are enrolled across the RESET™ clinical development program with 22 U.S. clinical sites now actively enrolling. We also announced a new CDMO agreement with Lonza and expansion of our existing automated manufacturing collaboration with Cellares. Read the press release here: https://lnkd.in/e3_ArMy3 #CART #celltherapy #reset #autoimmune

Cabaletta Bio attended the 2024 National Scleroderma Conference this weekend in Bellevue, WA. Many thanks to the National Scleroderma Foundation for organizing this important meeting and promoting disease awareness and education! Our RESET-SSc trial is open and recruiting patients: https://lnkd.in/ekZsvUiX #scleroderma #SSc

This morning Cabaletta Bio reported positive initial clinical data from the Phase 1/2 RESET-Myositis™ and RESET-SLE™ trials of CABA-201. Read our press release on the News & Media section of our website and join our live investor conference call and webcast today at 8:00 a.m. EDT here: https://lnkd.in/eFsVhdxz #CART #celltherapy #myositis #SLE #autoimmune

Cabaletta Bio's Phase 1/2 RESET-SSc trial is now recruiting individuals with systemic sclerosis. The study is evaluating the safety and efficacy of CABA-201, an investigational CD19-CAR T cell therapy. Systemic sclerosis is a rare autoimmune disease that can affect the skin and organs in the body such as the heart, lungs and kidneys. Learn more at the link below: https://lnkd.in/eUf5J3-Y #CART #celltherapy #autoimmune #scleroderma #SSc

Join us at our Satellite Symposium on June 14th at 8:15am CEST at the #EULAR2024 Congress in Vienna, Austria. We will have presentations from Georg Schett, a pioneer of CAR T cell therapy for the treatment of autoimmune diseases, and Carl June, a pioneer of the first CAR T cell therapy approved in oncology, as well as David J. Chang, MD, MPH, FACR, our Chief Medical Officer, sharing our initial clinical data with CABA-201 in myositis and lupus. Look forward to seeing you there! #EULAR2024 #CART #celltherapy #autoimmune

Cabaletta Bio's Phase 1/2 RESET-MG trial is now recruiting individuals with generalized myasthenia gravis. The study is evaluating the safety and efficacy of CABA-201, an investigational CD19-CAR T cell therapy. Myasthenia gravis is an autoimmune disease that results from antibodies that get in the way of signals between nerves and muscles, causing profound muscle weakness. Learn more at the link below: https://lnkd.in/ef9K3HW3 #CART #celltherapy #autoimmune #myastheniagravis #MG

Cabaletta Bio was grateful to be recognized on Tuesday night as the Healthcare Innovator of the Year at the 2024 Enterprise Awards hosted by the Philadelphia Alliance for Capital and Technologies (PACT). The shared vision and teamwork of the Crew have facilitated and accelerated our ability to develop potentially curative engineered cell therapies for patients with autoimmune disease. It is a privilege to be able to serve patients, families, and providers with our Crew members as part of the ecosystem across the region advancing innovative solutions within healthcare #PACT #2024EnterpriseAwards #CART #celltherapy #autoimmunedisease